Motiv8 Investments LLC Purchases 1,412 Shares of Gilead Sciences, Inc. $GILD

Motiv8 Investments LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,191 shares of the biopharmaceutical company’s stock after buying an additional 1,412 shares during the quarter. Motiv8 Investments LLC’s holdings in Gilead Sciences were worth $1,462,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the first quarter worth $29,000. Colonial Trust Advisors boosted its position in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Core Alternative Capital increased its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,402,130 over the last 90 days. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, Rothschild & Co Redburn raised their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $117.17.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $112.69 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company’s 50-day moving average price is $114.34 and its 200-day moving average price is $109.97. The company has a market cap of $139.83 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a twelve month low of $83.98 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.